Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Blisibimod in IgA Nephropathy
NCT02062684Phase 3Completed
- Sponsor
- Anthera Pharmaceuticals, Inc.
- Start
- Jun 2013
- Primary completion
- Mar 2017
- Modality
- Fc-Fusion Proteins
- Countries
- 10
01
Overview
Phase 3, randomised, double-blind trial in IgA nephropathy (IgAN) comparing Blisibimod with Placebo (2 arms). Primary endpoint: Proportion of subjects achieving reduction in proteinuria from baseline at 24 weeks. Started Jun 2013; status: completed.
02
Drugs
blisibimod
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on NCT02062684.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02062684.